Candel Therapeutics Secures EVERSANA Partnership for Potential U.S. Launch of Prostate Cancer Drug Aglatimagene Besadenovec
CADL sits 45% above its 52-week low of $4.338.
Summary
Candel Therapeutics has announced a commercialization agreement with EVERSANA to support the potential U.S. launch of its lead immunotherapy candidate, aglatimagene besadenovec, for intermediate- to high-risk, localized prostate cancer. This formal agreement follows the company's previously reported positive Phase 3 prostate cancer data and RMAT designation, as well as earlier mentions of pre-commercialization workstreams. EVERSANA will provide a broad range of commercialization services, including data and analytics, medical affairs, market access, and field operations, positioning Candel for a planned Biologics License Application (BLA) submission in Q4 2026. This partnership is a material step for the clinical-stage biopharmaceutical company, significantly de-risking the commercialization pathway for its lead asset and moving it closer to potential revenue generation. Investors will now focus on the upcoming BLA submission and subsequent regulatory review.
At the time of this announcement, CADL was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $454.1M. The 52-week trading range was $4.34 to $7.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.